SCHEMBL10178246

SCHEMBL10178246

Nc1ncc(Br)nc1-c1cc(-c2ccccc2)no1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATR Q13535 11/20 0.60
ATM Q13315 7/20 0.60
GSK3B P49841 3/20 0.60
NPC1 O15118 7/20 0.55
RAB9A P51151 7/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
PRKDC P78527 4/20 0.47
CASP3 P42574 1/20 0.47
SENP8 Q96LD8 1/20 0.47
SENP7 Q9BQF6 1/20 0.47
SENP6 Q9GZR1 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP2C9 P11712 1/20 0.46
HPGD P15428 1/20 0.46
NFKB1 P19838 1/20 0.46
CYP2C19 P33261 1/20 0.46
NFKB2 Q00653 1/20 0.46
RELA Q04206 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25043002 0.86 ATR (0.49) ATRATMGSK3BNPC1RAB9A
SCHEMBL13195749 0.86 ATR (0.57) ATRATMGSK3BNPC1RAB9A
SCHEMBL25042866 0.84 ATR (0.53) ATRATMGSK3BPRKDCJAK2
SCHEMBL25042621 0.83 ATR (0.47) ATRATMGSK3BPRKDCJAK2
SCHEMBL28402692 0.83 ATR (0.63) ATRATMGSK3BNPC1RAB9A
SCHEMBL506800 0.83 ATR (0.52) ATRATMGSK3BPRKDCJAK2
SCHEMBL10178207 0.81 RAB9A (0.49) ATRATMGSK3BNPC1RAB9A
SCHEMBL12987509 0.80 ATR (0.68) ATRATMGSK3BPRKDCJAK2
SCHEMBL2486197 0.80 ATR (0.66) ATRATMGSK3BPRKDCJAK2
SCHEMBL25042592 0.79 ATR (0.48) ATRATMGSK3BNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630956-B2 Compounds useful as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-04-25 US disclosed
EP-2694498-B1 AMINOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF TRA KINASE VERTEX PHARMA (US) 2016-03-30 EP disclosed
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-02 US disclosed
WO-2011143426-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027874-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, CHEK2 ATR 1/4885ATM 32/4885GSK3B 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.